Ⓐ
PeptiBrief
Investigational peptide

ACE-031

An investigational broad activin-receptor ligand trap that increased lean mass but was discontinued after vascular safety findings.

Evidence confidence

Human
3/5
Multiple human studies
2 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
3/5
Reasonable safety characterisation
2 citations

Claimed uses

Mechanisms

Safety notes

Clinical development identified nosebleeds and telangiectasia consistent with broad activin-family ligand trapping. Long-term vascular, reproductive and systemic safety was not established.

Regulation
  • Investigational development was discontinued and ACE-031 is not an approved medicine.

References

  1. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial · 2017
  2. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers · 2013
Last reviewed
11 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.